It works in the hindbrain (a different part of the brain than GLP-1) to tell you that you have had enough food
Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, parallel-group, phase 2 trial PMID: 37385280 Lancet
However, based on whats known about similar GLP-1 medications, appetite and weight may gradually return after discontinuation
Its not as good as the diabetic data, partially because its a much larger trial and partially because diabetics just seem to tolerate these medications better
Follow the injection instructions carefully to minimize irritation, clean the injection site before use, and avoid areas with scars or moles